These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 8921821)

  • 1. Short-term administration of intranasal or oral Hexarelin, a synthetic hexapeptide, does not desensitize the growth hormone responsiveness in human aging.
    Ghigo E; Arvat E; Gianotti L; Grottoli S; Rizzi G; Ceda GP; Boghen MF; Deghenghi R; Camanni F
    Eur J Endocrinol; 1996 Oct; 135(4):407-12. PubMed ID: 8921821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oestrogen replacement does not restore the reduced GH-releasing activity of Hexarelin, a synthetic hexapeptide, in post-menopausal women.
    Arvat E; Gianotti L; Broglio F; Maccagno B; Bertagna A; Deghenghi R; Camanni F; Ghigo E
    Eur J Endocrinol; 1997 May; 136(5):483-7. PubMed ID: 9186268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Age-related variations in the neuroendocrine control, more than impaired receptor sensitivity, cause the reduction in the GH-releasing activity of GHRPs in human aging.
    Arvat E; Ceda GP; Di Vito L; Ramunni J; Gianotti L; Broglio F; Deghenghi R; Ghigo E
    Pituitary; 1998 Apr; 1(1):51-8. PubMed ID: 11081183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of histaminergic antagonists on the GH-releasing activity of GHRH or hexarelin, a synthetic hexapeptide, in man.
    Arvat E; Maccagno B; Ramunni J; Gianotti L; Di Vito L; Deghenghi R; Camanni F; Ghigo E
    J Endocrinol Invest; 1997 Mar; 20(3):122-7. PubMed ID: 9186817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The GH, prolactin, ACTH and cortisol responses to Hexarelin, a synthetic hexapeptide, undergo different age-related variations.
    Arvat E; Ramunni J; Bellone J; Di Vito L; Baffoni C; Broglio F; Deghenghi R; Bartolotta E; Ghigo E
    Eur J Endocrinol; 1997 Dec; 137(6):635-42. PubMed ID: 9437229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Somatotrope responsiveness to Hexarelin, a synthetic hexapeptide, is refractory to the inhibitory effect of glucose in obesity.
    Grottoli S; Maccario M; Procopio M; Oleandri SE; Arvat E; Gianotti L; Deghenghi R; Camanni F; Ghigo E
    Eur J Endocrinol; 1996 Dec; 135(6):678-82. PubMed ID: 9025712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Growth hormone-releasing activity of growth hormone-releasing peptide-6 is maintained after short-term oral pretreatment with the hexapeptide in normal aging.
    Ghigo E; Arvat E; Rizzi G; Goffi S; Grottoli S; Mucci M; Boghen MF; Camanni F
    Eur J Endocrinol; 1994 Nov; 131(5):499-503. PubMed ID: 7952160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The GH-releasing effect of Hexarelin, a synthetic hexapeptide, in newborns is lower than in young adults.
    Bartolotta E; Bellone J; Aimaretti G; Arvat E; Benso L; Deghenghi R; Camanni F; Ghigo E
    J Pediatr Endocrinol Metab; 1997; 10(5):491-7. PubMed ID: 9401905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low hexarelin dose and pyridostigmine have additive effect and potentiate to the same extent the GHRH-induced GH response in man.
    Arvat E; Di Vito L; Ramunni J; Gianotti L; Giordano R; Deghenghi R; Camanni F; Ghigo E
    Clin Endocrinol (Oxf); 1997 Oct; 47(4):495-500. PubMed ID: 9404449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man. Comparison with the effects of GHRH, TRH and hCRH.
    Arvat E; di Vito L; Maccagno B; Broglio F; Boghen MF; Deghenghi R; Camanni F; Ghigo E
    Peptides; 1997; 18(6):885-91. PubMed ID: 9285939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hexarelin, a synthetic GH-releasing peptide, is a powerful stimulus of GH secretion in pubertal children and in adults but not in prepubertal children and in elderly subjects.
    Bellone J; Bartolotta E; Sgattoni C; Aimaretti G; Arvat E; Bellone S; Deghenghi R; Ghigo E
    J Endocrinol Invest; 1998 Sep; 21(8):494-500. PubMed ID: 9801989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Arginine enhances the growth hormone-releasing activity of a synthetic hexapeptide (GHRP-6) in elderly but not in young subjects after oral administration.
    Ghigo E; Arvat E; Rizzi G; Bellone J; Nicolosi M; Boffano GM; Mucci M; Boghen MF; Camanni F
    J Endocrinol Invest; 1994 Mar; 17(3):157-62. PubMed ID: 8051337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adrenocorticotropin- and cortisol-releasing effect of hexarelin, a synthetic growth hormone-releasing peptide, in normal subjects and patients with Cushing's syndrome.
    Ghigo E; Arvat E; Ramunni J; Colao A; Gianotti L; Deghenghi R; Lombardi G; Camanni F
    J Clin Endocrinol Metab; 1997 Aug; 82(8):2439-44. PubMed ID: 9253314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intranasal administration of His-D-Trp-Ala-Trp-D-Phe-LysNH2 (growth hormone releasing peptide) increased plasma growth hormone and insulin-like growth factor-I levels in normal men.
    Hayashi S; Okimura Y; Yagi H; Uchiyama T; Takeshima Y; Shakutsui S; Oohashi S; Bowers CY; Chihara K
    Endocrinol Jpn; 1991 Feb; 38(1):15-21. PubMed ID: 1915110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man.
    Ghigo E; Arvat E; Gianotti L; Imbimbo BP; Lenaerts V; Deghenghi R; Camanni F
    J Clin Endocrinol Metab; 1994 Mar; 78(3):693-8. PubMed ID: 8126144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduction of the somatotrope responsiveness to GHRH and Hexarelin but not to arginine plus GHRH in hyperprolactinemic patients.
    Grottoli S; Razzore P; Arvat E; Oleandri SE; Rossetto R; Ciccarelli E; Camanni F; Ghigo E
    J Endocrinol Invest; 1997 Nov; 20(10):597-602. PubMed ID: 9438917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Arginine and growth hormone-releasing hormone restore the blunted growth hormone-releasing activity of hexarelin in elderly subjects.
    Arvat E; Gianotti L; Grottoli S; Imbimbo BP; Lenaerts V; Deghenghi R; Camanni F; Ghigo E
    J Clin Endocrinol Metab; 1994 Nov; 79(5):1440-3. PubMed ID: 7962341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The IGF-I response to very low rhGH doses is preserved in human ageing.
    Arvat E; Ceda G; Ramunni J; Lanfranco F; Aimaretti G; Gianotti L; Broglio F; Ghigo E
    Clin Endocrinol (Oxf); 1998 Dec; 49(6):757-63. PubMed ID: 10209563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tripartite neuroendocrine activation of the human growth hormone (GH) axis in women by continuous 24-hour GH-releasing peptide infusion: pulsatile, entropic, and nyctohemeral mechanisms.
    Shah N; Evans WS; Bowers CY; Veldhuis JD
    J Clin Endocrinol Metab; 1999 Jun; 84(6):2140-50. PubMed ID: 10372723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustained elevation of pulsatile growth hormone (GH) secretion and insulin-like growth factor I (IGF-I), IGF-binding protein-3 (IGFBP-3), and IGFBP-5 concentrations during 30-day continuous subcutaneous infusion of GH-releasing peptide-2 in older men and women.
    Bowers CY; Granda R; Mohan S; Kuipers J; Baylink D; Veldhuis JD
    J Clin Endocrinol Metab; 2004 May; 89(5):2290-300. PubMed ID: 15126555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.